Skip to content
  1. Home
  2. >Life Sciences
  3. >Focus Areas
  4. >Mash

Accelerating Therapeutic Development

MASH GenoSphere™ clinico-genomic cohort

Accelerate therapeutic development by accessing Helix's comprehensive and rapidly growing MASH GenoSphere multimodal dataset. Built on the world's most dynamic precision clinical research network, our data ecosystem integrates longitudinal clinical data and cutting-edge Exome+® sequencing designed to support the development of next-generation precision therapies.

Connect with Us
Abstarct shapes with blue and other light colors for the background

Curated, longitudinal MASH-enriched Cohort of over 17,000 Linked Clinico-Genomic Records to Accelerate Drug Discovery and Development


Approximately 22 million adult Americans are affected by MASH, a severe inflammatory form of metabolic dysfunction-associated steatotic liver disease (MASLD). Helix’s growing MASH GenoSphere clinico-genomic dataset consists of consists of whole Exome+ sequencing profiles for >10k consented individuals paired with longitudinal clinical data spanning decades including demographics, related diagnoses, major lab results including Fibrosis-4 (FIB-4) scores , past procedures and insights, with the ability to link medical and mortality claims data.

Cohort Highlights

>17,000

MASH linked clinico-genomic cohort with ~16K with High-Risk and >1K MASH affected records

>90%

of cohort with FIB-4 scores above >2.67 which is associated with severe liver fibrosis

~15 years average

longitudinal patient EHR history including diagnoses, lab results, procedures, prescriptions and more

Longitudinal Clinical Insights

Multiple Lab measurements spanning years

Longitudinal clinical insights with multiple measurements for key lab results including Platelet counts, ALT, AST, HBA1c and many more giving a comprehensive clinical journey.

Body Mass Index (BMI) breakdown

Higher BMI are shown to be positively correlated with metabolic syndrome and MASH. >70% of our MASH records have a BMI classified as Overweight or Obese.

Helix Advantages

Longitudinal Clinical Insights

De-identified, OMOP-standardized EHR integrations, including full clinical data & lab results, across North America. Regular data refreshes enable life sciences to follow the patient journey beyond an initial encounter.

Whole Exome+ Sequencing

Deep genomic insights using Helix’s comprehensive and proprietary exome platform covering hundreds of genes implicated in cardiovascular, metabolic, and other related diseases.

Patient Consent

Full consent for recontact for enrollment in research studies, clinical trials, and surveys.

World class Analytical Capabilities

Dedicated in-house translational research team to support life sciences’ analytical and research needs.

Additional Resources

Helix GenoSphere™

Helix GenoSphere™

Read More

Webinars

Metabolic risk factors and BMI-associated variants influencing weight loss with Semaglutide

Read More

Press Releases

Helix GenoSphere™ Launches MASH-Enriched Cohort of Over 17,000 Linked Clinico-Genomic Records to Accelerate Drug Discovery and Development

Read More

Connect with us!